Advertisement

Topics

Novartis' Entresto helps preserve kidney function in chronic heart failure patients

05:56 EDT 16 Apr 2018 | Pharmafile

Novartis has lifted the curtain on new data from a Phase 3 trial investigating the efficacy of Entresto (sacubitril/valsartan) in preserving kidney function in patients with heart failure with reduced ejection fraction (HFrEF), demonstrating that those taking the drug experienced a slower rate of decline in estimated glomerular filtration rate (eGFR).

read more

Original Article: Novartis' Entresto helps preserve kidney function in chronic heart failure patients

NEXT ARTICLE

More From BioPortfolio on "Novartis' Entresto helps preserve kidney function in chronic heart failure patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...